Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3′, 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof
    10.
    发明授权
    Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3′, 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof 有权
    (4S)-4-乙基-4-羟基-11- [2-(三甲基甲硅烷基)乙基] -1H-吡喃并[3',4':6,7]中氮茚并[1,2-b] 3,4(4H,12H) - 二酮及其使用方法

    公开(公告)号:US08569265B2

    公开(公告)日:2013-10-29

    申请号:US13068244

    申请日:2011-05-06

    IPC分类号: A61K31/695 C07F7/02

    摘要: The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

    摘要翻译: 本发明公开了:(i)两种新型氘代Karenitecin?类似物,其药学上可接受的盐和/或衍生物; (ii)合成所述新型氘化Karenitecin®类似物,其药学上可接受的盐和/或衍生物的方法; (iii)药学上可接受的制剂,其包含所述新型氘代Karenitecin?类似物,其药学上可接受的盐,衍生物; 和/或任选的一种或多种另外的化学治疗剂; 和(iv)所述新型氘化Karenitecin®类似物,其药学上可接受的盐,衍生物的给药方法; 和/或任选的一种或多种另外的化学治疗剂给予有需要的受试者。